Strategic partnerships Opportunity to pursue collaborations with major cardiovascular device manufacturers and hospital systems by positioning MobiusHD as a complementary endovascular platform for heart failure and high-risk hypertensive patients, leveraging existing investor-backed funding to de-risk joint ventures.

Clinical expansion Target hospitals and academic centers conducting baroreflex modulation and endovascular trials to accelerate patient recruitment and gather real-world outcomes, converting early adopters into champions for broader clinical adoption.

Financial leverage Utilize the company’s $105M funding history and modest current revenue to engage investors and strategic buyers with co-development or licensing prospects, highlighting upside from scalable EVBA technology in cardiovascular disease markets.

Market readiness Highlight the addressable underserved patient segment for heart failure and hypertension where conventional therapies fall short, aligning messaging with payer value propositions around reduced sympathetic tone and potential hospitalization avoidance.

Tech and data Emphasize the platform’s neural modulation mechanism and ongoing clinical evaluations to attract early adopters and researchers, offering collaboration on data sharing, registries, and post-market studies to support evidence generation and market credibility.